Universitätsklinikum Gießen und Marburg (UKGM)

Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis (2020) Taylan C, Driemeyer J, Schmitt CP, Pape L, Büscher R, Galiano M, König J, et al. Journal article Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD) (2020) Burgmaier K, Ariceta G, Bald M, Buescher AK, Burgmaier M, Erger F, Gessner M, et al. Journal article Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, et al. Conference contribution Frühgeborene an der Grenze der Lebensfähigkeit (Entwicklungsstufe S2k, AWMF-Leitlinien-Register Nr024/019, Juni 2020) (2020) Bührer C, Felderhoff-Müser U, Gembruch U, Hecher K, Kainer F, Kehl S, Kidszun A, et al. Journal article Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different prognostic scores (2020) Riecke K, Mueller , Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia with ASXL1-, RUNX1- and TP53 mutations (2020) Egger-Heidrich K, Middeke JM, Schaefer-Eckart K, Kaufmann M, Einsele H, Mueller-Tidow C, Rösler W, et al. Conference contribution Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, et al. Journal article Usage of antiepileptic drugs in different diseases in Germany – A retrospective study (2020) Scholten J, Hamer H, Kostev K Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution